Direkt zum Inhalt
Merck

Fortfahren mit

1448901

USP

Mupirocin

United States Pharmacopeia (USP) Reference Standard

Synonym(e):

5,9-Anhydro-2,3,4,8-tetradeoxy-8-[[3-(2-hydroxy-1-methylpropyl)oxiranyl]methyl]-3-methyl-[2E,8[2S,3S(1S,2S)]]-L-talonon-2-enonic acid 8-carboxyoctyl ester, BRL 4910A, Pseudomonic acid

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Ansicht ändern
PackungsgrößeSKUVerfügbarkeitPreis
50 mg
Warenkorb auf Verfügbarkeit prüfen
€ 407,00

Über diesen Artikel

Empirische Formel (Hill-System):
C26H44O9
CAS-Nummer:
Molekulargewicht:
500.62
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:

€ 407,00


Warenkorb auf Verfügbarkeit prüfen

Großbestellung anfragen
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten


grade

pharmaceutical primary standard

API family

mupirocin

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

[H][C@@]1(CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O)C[C@@H]2O[C@@]2([H])[C@@H](C)[C@H](C)O

InChI

1S/C26H44O9/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29)/b16-13+/t17-,18-,19-,20-,21-,24+,25-,26-/m0/s1

InChI key

MINDHVHHQZYEEK-HBBNESRFSA-N

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Mupirocin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Biochem/physiol Actions

Antibiotic; inhibits isoleucyl-tRNA synthetase (IRS).

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 1

Dieser Artikel
M7694PHR28061448923
Mupirocin United States Pharmacopeia (USP) Reference Standard

USP

1448901

Mupirocin

manufacturer/tradename

USP

manufacturer/tradename

-

manufacturer/tradename

-

manufacturer/tradename

USP

grade

pharmaceutical primary standard

grade

-

grade

pharmaceutical secondary standard

grade

pharmaceutical primary standard

application(s)

pharmaceutical (small molecule)

application(s)

-

application(s)

pharmaceutical

application(s)

pharmaceutical (small molecule)

format

neat

format

-

format

-

format

neat

API family

mupirocin

API family

-

API family

mupirocin

API family

mupirocin


Still not finding the right product?

Explore all of our products under Mupirocin


Lagerklasse

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable



Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen



M E H Jaspers et al.
Burns : journal of the International Society for Burn Injuries, 40(8), 1570-1574 (2014-04-02)
Staphylococcus aureus wound colonization frequently occurs in patients with burns and can cause impaired wound healing. Nasal mupirocin application may contribute to the reduction of burn wound colonization of endogenous origin, whereas colonization by the exogenous route can be reduced
Alexander J Kallen et al.
Infection control and hospital epidemiology, 26(12), 916-922 (2006-01-19)
To review the evidence evaluating perioperative intranasal mupirocin for the prevention of surgical-site infections according to type of surgical procedure. Systematic review and meta-analysis of published clinical trials. Studies included were either randomized clinical trial or prospective trials at a
Kevin B Laupland et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 37(7), 933-938 (2003-09-18)
Most Staphylococcus aureus infections are endogenously acquired, and treatment of nasal carriage is one potential strategy for prevention. We critically appraised the published evidence regarding the efficacy of intranasal mupirocin for eradication of S. aureus nasal carriage and for prophylaxis



Global Trade Item Number

SKUGTIN
1448901-50MG04061833860557

Questions

Reviews

No rating value

Active Filters